ConductScience.org, home

Paper39155294

Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.

Mongeon B and 8 others. NPJ Syst Biol Appl, 2024. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies. Papers, record 39155294. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39155294

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies.
PubMed
Journal
NPJ Syst Biol Appl
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
1.5, provisional
iCite
Revised in PubMed
2024-08-21
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mongeon BBlanchehttps://orcid.org/0000-0001-9324-5012
2Hébert-Doutreloux JJulien
3Surendran AAnudeephttps://orcid.org/0000-0003-0777-4642
4Karimi EElham
5Fiset BBenoit
6Quail DFDaniela F
7Walsh LALogan A
8Jenner ALAdrianne L
9Craig MMorganhttps://orcid.org/0000-0003-4852-4770

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlioblastomaMajor topic
Tumor MicroenvironmentMajor topic
ImmunotherapyMajor topic
Brain NeoplasmsMajor topic
Computer SimulationMajor topic
Humans
Oncolytic Virotherapy
Oncolytic Viruses
Immune Checkpoint Inhibitors

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
RGPIN-2018-04546Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada)RGPIN201804PubMed

Source NIH RePORTER

Download CSV of grants

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115758009Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med2005https://conductscience.org/library/papers/15758009PubMed
226960561Survival in glioblastoma: a review on the impact of treatment modalities.Clin Transl Oncol2016https://conductscience.org/library/papers/26960561PubMed
335327456Assessing the Future of Solid Tumor Immunotherapy.Biomedicines2022https://conductscience.org/library/papers/35327456PubMed
417997439History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.J Urol2008https://conductscience.org/library/papers/17997439PubMed
526056592Adoptive T-cell therapy for Leukemia.Mol Cell Ther2014https://conductscience.org/library/papers/26056592PubMed
634236546Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.Cancer Metastasis Rev2021https://conductscience.org/library/papers/34236546PubMed
735337133Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/35337133PubMed
832266483Oncolytic Viruses for the Treatment of Metastatic Melanoma.Curr Treat Options Oncol2020https://conductscience.org/library/papers/32266483PubMed
932004650Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.J Am Acad Dermatol2020https://conductscience.org/library/papers/32004650PubMed
1026059190Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.Clin Cancer Res2015https://conductscience.org/library/papers/26059190PubMed
1132437507Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.JAMA Oncol2020https://conductscience.org/library/papers/32437507PubMed
1235511454Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.Neuro Oncol2022https://conductscience.org/library/papers/35511454PubMed
1331289361Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.Oncogene2019https://conductscience.org/library/papers/31289361PubMed
1435637733Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy.iScience2022https://conductscience.org/library/papers/35637733PubMed
1537853118Clinical trial links oncolytic immunoactivation to survival in glioblastoma.Nature2023https://conductscience.org/library/papers/37853118PubMed
1630261620The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.Cancers (Basel)2018https://conductscience.org/library/papers/30261620PubMed
1737188783Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med2023https://conductscience.org/library/papers/37188783PubMed
1833608375In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.J Immunother Cancer2021https://conductscience.org/library/papers/33608375PubMed
1920234341Synergistic interaction between oncolytic viruses augments tumor killing.Mol Ther2010https://conductscience.org/library/papers/20234341PubMed
2019603003Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Mol Ther2009https://conductscience.org/library/papers/19603003PubMed

See all 57 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
41557745Therapeutic targeting of oligodendrocytes in an agent-based model of multiple sclerosis.PLoS Comput Biol2026https://conductscience.org/library/papers/41557745PubMed
41501087Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment.NPJ Syst Biol Appl2026https://conductscience.org/library/papers/41501087PubMed
41270976Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.Adv Drug Deliv Rev2026https://conductscience.org/library/papers/41270976PubMed
41080585Targeting immune cell migration as therapy for inflammatory disease: a review.Front Immunol2025https://conductscience.org/library/papers/41080585PubMed
41030523Targeting the tumor microenvironment in pediatric gliomas: Advances and future directions in immunotherapy.Neurooncol Adv2025https://conductscience.org/library/papers/41030523PubMed
40995359Targeting the neuroimmune axis in glioblastoma: emerging strategies for precision immunotherapy.Front Immunol2025https://conductscience.org/library/papers/40995359PubMed
40907963Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling.J Am Med Inform Assoc2026https://conductscience.org/library/papers/40907963PubMed
40840524Systems biology successes and areas for opportunity in prostate cancer.Endocr Relat Cancer2025https://conductscience.org/library/papers/40840524PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39155294

GET https://conductscience.org/api/papers/v1/39155294/references?page=2